We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Fragmented Red Blood Cell Measurement Automated

By LabMedica International staff writers
Posted on 02 Jul 2012
Print article
Image: Schistocytes in blood smear (Photo courtesy of Dr. Paulo H.O. Mourao).
Image: Schistocytes in blood smear (Photo courtesy of Dr. Paulo H.O. Mourao).
The laboratory diagnosis of thrombotic microangiopathies (TMA) or disorders that may mimic their features remains difficult.

The detection of schistocytes on the blood smear is a cornerstone finding to assess the diagnosis, but microscopic evaluation of schistocytes is still problematic with wide inter-observer variations.

Hematologists at the University Hospital (Nancy, France) conducted studies comparing automated and microscopic counts of Fragmented Red Blood Cells (FRC) and schistocytes. The data came from the day-to-day analysis of more than 90,000 peripheral blood (PB) samples for 10 years in four centers. More than 900 patients were examined because of a clinical suspicion of TMA and 17 samples were derived from preterm newborns who were supposed to give the highest FRC counts among nonpathologic samples.

FRC were counted by automated direct measurement using the two automated analyzers (ABCC): the ADVIA 120 analyzer (Siemens; Tarrytown, NY, USA) and the XE-2100 analyzer (Sysmex; Kobe, Japan). Schistocyte counting was carried out from May-Grünwald-Giemsa-stained PB smears. The reference range for FRC was less than 0.3% for the ADVIA and less than 0.5% for the Sysmex XE-2100.

The correlation coefficient for Siemens devices was around 0.7. The main problem resulted from an overestimation of FRC as compared to schistocytes from 0.4% to 0.5% for a count of schistocyte ranging from 0% to 1.5%. Conversely, the scientists observed an underestimation of FRC as compared to schistocytes subsequent to this 1.5% threshold. For the Sysmex XE-2100 counter, the overestimation of the FRC was more pronounced, at less 0.8%, and increased slightly with high schistocyte percentages. The presence of FRC below a threshold determined at 1% for both automated analyzers had a negative predictive value (PV) close to 100% to exclude the presence of schistocyte on the blood smear, but in relationship with a poor positive PV value.

The authors concluded that that systematic quantification of FRC might improve the laboratorians' ability to exclude samples with schistocytes. This should be especially useful among patients in whom TMA diagnosis is suspected. However, several limitations deserve consideration such as few false-negative FRC counts in a context of macrocytosis, great lack of specificity. Hence, a PB smear examination was still advised for the validation of the count if needed. The study was published on June 14, 2012, in the International Journal of Laboratory Hematology.

Related Links:

University Hospital
Siemens
Sysmex


Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Centrifuge
Hematocrit Centrifuge 7511M4
New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.